Livzon Pharmaceutical Group Inc. (01513.HK): Application for marketing license of Lecantixumab injection accepted by National Medical Products Administration.

China Fortune Financial News APP News, Luye Pharma (01513.HK) announced that its controlling subsidiary, Zhuhai Luye Monoclonal Antibody Biotechnology Co., Ltd. (Luye Monoclonal Antibody), has received the "Acceptance Notice" (Acceptance No.: CXSS2500144) issued by the National Medical Products Administration. The application for domestic production and market authorization of Riconcicuta Monoclonal Antibody Injection jointly developed by Luye Monoclonal Antibody and Beijing Xinkanghe Biomedical Technology Co., Ltd. has been accepted by the National Medical Products Administration.